Latest Breaking News On - Japan oncology group - Page 1 : comparemela.com

Amgen s Lumakras data and research shows positive results

Research has reinforced the efficacy of Lumakras (sotorasib), a small molecule inhibitor in advanced non-small cell lung cancer (NSCLC) and metastatic colorectal cancer (mCRC).

United statesDavid hongMelissa johnsonDavid reeseDavids hongSarah cannon research institute at tennessee oncologyAmerican society of clinical oncologyUniversity of texas md anderson cancer centerJapan oncology groupLung cancer researchAmerican societyClinical oncologyWest japan oncology groupSarah cannon research instituteInvestigational cancer therapeuticsCancer center

AMGEN PRESENTS NEW LUMAKRAS CODEBREAK 200 CNS DATA AT ASCO 2023

THOUSAND OAKS - Amgen today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global development program in patients with KRAS G12C-mutated. | June 5, 2023

United statesPuerto ricoSaudi arabiaMacau generalSouth koreaUnited arab emiratesUnited kingdomHong kongGreat britainDavidm reeseJessica akopyanDavids hongMelissal johnsonEuropean unionKyowa kirin co ltdDrug administration

AMGEN PRESENTS NEW LUMAKRAS® (SOTORASIB) CODEBREAK 200 CNS DATA AT ASCO 2023

/PRNewswire/ Amgen (NASDAQ:AMGN) today announced the presentation of new data from the CodeBreaK clinical trial program, the most comprehensive global.

United arab emiratesUnited statesSouth koreaHong kongSaudi arabiaPuerto ricoMacau generalUnited kingdomGreat britainCelllung cancerandJessica akopyanDavids hongStevens johnsonMichael strapazonMelissal johnsonSpira al

Anesthesia Use in Idiopathic Pulmonary Fibrosis

Complications, dominated by postoperative pulmonary complications, poses a significant barrier to safe perioperative care of Idiopathic Pulmonary Fibrosis

United statesSouth koreaStowassers comorbiditiesIsomotoh perioperativeGen thorac cardiovascLees perioperativeKyobu gekaClin respirColl cardiolAnesth analgJapan oncology groupIndian chest societyNational college of chest physiciansOpin pulmChens yYehw s

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial

Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial
thelancet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thelancet.com Daily Mail and Mail on Sunday newspapers.

United statesLe chevalierEuropean organization for researchJapan oncology groupJapan lung cancer societyEnglj medRev clin oncolClin oncolEuropean organizationNatl cancer instLife questionnaireThorac oncolNational hospital organization study groupLung cancerSouthern california regional cancer registryWest japan oncology group